fbpx
QQQ
+ 0.00
342.63
+ 0%
DIA
-0.17
333.13
-0.05%
SPY
+ -0.02
414.94
+ 0%
TLT
+ 0.00
145.73
+ 0%
GLD
+ 0.05
164.88
+ 0.03%

Aleafia Q1 Revenue Drops 51% YoY, Medical And Rec Cannabis Revenue Increases, Reflects Product Portfolio Expansion

May 11, 2021 11:46 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Aleafia Q1 Revenue Drops 51% YoY, Medical And Rec Cannabis Revenue Increases, Reflects Product Portfolio Expansion

Aleafia Health Inc. (TSX:AH) (OTCQX:ALEAF) revealed Tuesday its revenue had dropped by 51% year-over-year to $7.07 million in the first three months of 2021.

Cannabis net revenue decreased over the same period by 55% to $6.24 million, whereas net medical cannabis revenue and net adult-use cannabis revenue spiked 95% and 143%, respectively.

Net bulk wholesale cannabis revenue amounted to roughly $1.9 million, representing an 84% decrease year-over-year.

Geoffrey Benic, CEO of the Toronto-based company, said the exponential increase in the cannabis product portfolio resulted in "substantial improvements in the profitability of our core adult-use and medical cannabis product sales, contrasting with the broader industry trend of price and margin compression."

Here's a breakdown of what the first quarter 2021 earnings report showed:

  • Adjusted gross profit before fair value adjustments on net cannabis revenue shrunk to $3.7 million from $11.7 million in the corresponding quarter of 2020.
  • Adjusted gross margin, before fair value adjustments, on net cannabis revenue was 59% versus 85% in the prior year.
  • Selling, general and administrative expenses increased to $8.35 million, from $6.1 million in the same period of 2020.
  • Gross profit dropped by 60% year-over-year to $2.4 million.
  • Adjusted EBITDA came in negative at $3.03 million versus a gain of roughly $6.8 million in the first quarter of 2021.
  • Net loss spiked 83% year over year to $11.25 million.

Aleafia recently secured some $22.7 million in financing through a previously announced deal offering of some 27.39 million of its units at 83 cents per unit.

"To further leverage product portfolio expansion, we have only just begun the deployment of our highly differentiated medical cannabis ecosystem through the trailblazing exclusive agreement with Unifor," Benic disclosed.

Photo by Kimzy Nanney on Unsplash

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to our YouTube channel.


Related Articles

Aleafia Health Launches New CBD Freshly Minted Roll-on Under Noon & Night Brand Name

Aleafia Health Inc. (TSX: AH) (OTCQX: ALEAF) announced the launch of a new product Monday under its Noon & Night brand. CBD Freshly Minted Roll-on is a peppermint-scented product developed to provide a “soothing, aromatic experience” for cannabis connoisseurs. read more

Aleafia Health Cannabis Co To Raise Up To $30M Through ATM Program

Vertically integrated cannabis company Aleafia Health Inc. (TSX: AH) (OTCQX: ALEAF) is poised to raise up to $30 million through the newly established at-the-market equity program. read more

Aleafia Health Completes Export Of Medical Cannabis To Germany

Cannabis wellness company Aleafia Health Inc. (TSX: AH) (OTCQX: ALEAF) has completed its first shipment of signature THC cultivar Sour Kush to Germany. read more

Video: Benzinga Cannabis Insider 5/11 Ft. Aleafia CEO Geoffrey Benic Talking Earnings, Europe, And More

Benzinga’s Cannabis Insider is a live daily show for cannabis investors. read more